Keytruda

Merck & Co to buy IO specialists Immune Design for $300m

The move is aimed at helping the pharma giant consolidate its dominance in the field of immunotherapy (IO), where its checkpoint inhibitor Keytruda leads with annual sales of $7bn in 2018.

2019: CRISPR and therapeutic gene editing comes of age

The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

Merck puts prostate cancer firmly in Keytruda’s sights

In the Keytruda plus Lynparza arm, 12% of patients had a 50% or greater reduction in PSA, a biomarker which is elevated in prostate cancer. ... Meanwhile, the chemotherapy combination had a PSA response rate of 31%, while for the Keytruda/Xtandi group it

Immuno-oncology in 2019: the rapid evolution continues

PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

Keytruda combo outshines Opdivo in kidney cancer

Kidney cancer is one of the few therapy areas where BMS has had the upper hand on Merck &Co’s Keytruda, but new data on its use in combination with ... However the huge momentum and weight of data behind Keytruda makes its expansion into this field a

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]